11 research outputs found
Smoothing a rugged protein folding landscape by sequence-based redesign
The rugged folding landscapes of functional proteins puts them at risk of misfolding and aggregation.
Serine protease inhibitors, or serpins, are paradigms for this delicate balance between function and
misfolding. Serpins exist in a metastable state that undergoes a major conformational change in
order to inhibit proteases. However, conformational labiality of the native serpin fold renders them
susceptible to misfolding, which underlies misfolding diseases such as α1-antitrypsin deficiency. To
investigate how serpins balance function and folding, we used consensus design to create conserpin,
a synthetic serpin that folds reversibly, is functional, thermostable, and polymerization resistant.
Characterization of its structure, folding and dynamics suggest that consensus design has remodeled
the folding landscape to reconcile competing requirements for stability and function. This approach
may offer general benefits for engineering functional proteins that have risky folding landscapes,
including the removal of aggregation-prone intermediates, and modifying scaffolds for use as protein
therapeutics
Smoothing a rugged protein folding landscape by sequence-based redesign
The rugged folding landscapes of functional proteins puts them at risk of misfolding and aggregation. Serine protease inhibitors, or serpins, are paradigms for this delicate balance between function and misfolding. Serpins exist in a metastable state that undergoes a major conformational change in order to inhibit proteases. However, conformational labiality of the native serpin fold renders them susceptible to misfolding, which underlies misfolding diseases such as -antitrypsin deficiency. To investigate how serpins balance function and folding, we used consensus design to create , a synthetic serpin that folds reversibly, is functional, thermostable, and polymerization resistant. Characterization of its structure, folding and dynamics suggest that consensus design has remodeled the folding landscape to reconcile competing requirements for stability and function. This approach may offer general benefits for engineering functional proteins that have risky folding landscapes, including the removal of aggregation-prone intermediates, and modifying scaffolds for use as protein therapeutics.BTP is a Medical Research Council Career Development Fellow. AAN and JJH are supported by the Wellcome Trust (grant number WT 095195). SM acknowledges fellowship support from the Australian Research Council (FT100100960). NAB is an Australian Research Council Future Fellow (110100223). GIW is an Australian Research Council Discovery Outstanding Researcher Award Fellow (DP140100087). AMB is a National Health and Medical Research Senior Research Fellow (1022688). JCW is an NHMRC Senior Principal Research fellow and also acknowledges the support of an ARC Federation Fellowship. We thank the Australian Synchrotron for beam-time and technical assistance. This work was supported by the Multi-modal Australian ScienceS Imaging and Visualisation Environment (MASSIVE) (www.massive.org.au). We acknowledge the Monash Protein Production Unit and Monash Macromolecular Crystallization Facilit
Genetic diversity among some canola cultivars as revealed by RAPD, SSR and AFLP analyses
Ameloblastin Inhibits Cranial Suture Closure by Modulating Msx2 Expression and Proliferation
Deformities of cranial sutures such as craniosynostosis and enlarged parietal foramina greatly impact human development and quality of life. Here we have examined the role of the extracellular matrix protein ameloblastin (Ambn), a recent addition to the family of non-collagenous extracellular bone matrix proteins, in craniofacial bone development and suture formation. Using RT-PCR, western blot and immunohistochemistry, Ambn was localized in mouse calvarial bone and adjacent condensed mesenchyme. Five-fold Ambn overexpression in a K14-driven transgenic mouse model resulted in delayed posterior frontal suture fusion and incomplete suture closure. Moreover, Ambn overexpressor skulls weighed 13.2% less, their interfrontal bones were 35.3% thinner, and the width between frontal bones plus interfrontal suture was 14.3% wider. Ambn overexpressing mice also featured reduced cell proliferation in suture blastemas and in mesenchymal cells from posterior frontal sutures. There was a more than 2-fold reduction of Msx2 in Ambn overexpressing calvariae and suture mesenchymal cells, and this effect was inversely proportionate to the level of Ambn overexpression in different cell lines. The reduction of Msx2 expression as a result of Ambn overexpression was further enhanced in the presence of the MEK/ERK pathway inhibitor O126. Finally, Ambn overexpression significantly reduced Msx2 down-stream target gene expression levels, including osteogenic transcription factors Runx2 and Osx, the bone matrix proteins Ibsp, ColI, Ocn and Opn, and the cell cycle-related gene CcnD1. Together, these data suggest that Ambn plays a crucial role in the regulation of cranial bone growth and suture closure via Msx 2 suppression and proliferation inhibition
Activation of the JAK-STAT Signaling Pathway after In Vitro Stimulation with IFNĂź in Multiple Sclerosis Patients According to the Therapeutic Response to IFNĂź
Impairment of Type I but Not Type III IFN Signaling by Hepatitis C Virus Infection Influences Antiviral Responses in Primary Human Hepatocytes
Critical Significance of the Region between Helix 1 and 2 for Efficient Dominant-Negative Inhibition by Conversion-Incompetent Prion Protein
Regional and subtype-dependent miRNA signatures in sporadic Creutzfeldt-Jakob disease are accompanied by alterations in miRNA silencing machinery and biogenesis
Increasing evidence indicates that microRNAs (miRNAs) are contributing factors to neurodegeneration. Alterations in miRNA signatures have been reported in several neurodegenerative dementias, but data in prion diseases are restricted to ex vivo and animal models. The present study identified significant miRNA expression pattern alterations in the frontal cortex and cerebellum of sporadic Creutzfeldt-Jakob disease (sCJD) patients. These changes display a highly regional and disease subtype-dependent regulation that correlates with brain pathology. We demonstrate that selected miRNAs are enriched in sCJD isolated Argonaute(Ago)-binding complexes in disease, indicating their incorporation into RNA-induced silencing complexes, and further suggesting their contribution to disease-associated gene expression changes. Alterations in the miRNA-mRNA regulatory machinery and perturbed levels of miRNA biogenesis key components in sCJD brain samples reported here further implicate miRNAs in sCJD gene expression (de)regulation. We also show that a subset of sCJD-altered miRNAs are commonly changed in Alzheimer's disease, dementia with Lewy bodies and fatal familial insomnia, suggesting potential common mechanisms underlying these neurodegenerative processes. Additionally, we report no correlation between brain and cerebrospinal fluid (CSF) miRNA-profiles in sCJD, indicating that CSF-miRNA profiles do not faithfully mirror miRNA alterations detected in brain tissue of human prion diseases. Finally, utilizing a sCJD MM1 mouse model, we analyzed the miRNA deregulation patterns observed in sCJD in a temporal manner. While fourteen sCJD-related miRNAs were validated at clinical stages, only two of those were changed at early symptomatic phase, suggesting that the miRNAs altered in sCJD may contribute to later pathogenic processes. Altogether, the present work identifies alterations in the miRNA network, biogenesis and miRNA-mRNA silencing machinery in sCJD, whereby contributions to disease mechanisms deserve further investigation.This work was supported by the Robert Koch Institute through funds from the Federal Ministry of Health (grant no. 1369-341) to IZ, by the Seventh Framework Program of the European Commission (Grant No. 278486 [DEVELAGE project]), by the Spanish Ministry of Health, Instituto Carlos III (Fondo de Investigación Sanitaria [FIS] PI1100968, FIS PI14/00757 and by CIBERNED (Network center for biomedical research of neurodegenerative diseases) project BESAD-P to IF, by the Spanish Ministry of Health, Instituto Carlos III-Fondo Social Europeo (CP16/00041) to FL, by the Red Nacional de priones (AGL2015-71764-REDT- MINECO) to JADR, FL, IZ, JMT and IF, by the bilateral IKYDA project (ID 57260006) to FL, IZ and TS, by the Spanish Ministry of Economy and Competitiveness (BFU2016-80039-R) (AEI/MINEICO/FEDER, UE) and the “Maria de Maeztu” Program for Units of Excellence in R&D (MDM-2014-0370) to JD, by the Spanish Ministry of Economy and Competitiveness (SAF2014-60551-R) to EM and by the Spanish Ministry of Economy, Industry and Competitiveness (MEICO) (BFU2015-67777-R), the Generalitat de Catalunya (SGR2014-1218), CIBERNED (PRY-2016-2, MFDEND), La Caixa Obra Social Foundation and La Marató de TV3 to JADR